Unicycive Therapeutics stock sits 47.03 percent below its 52-week high

Unicycive Therapeutics stock stood at USD 4.63 on Nasdaq on September 28, 2026, down USD 0.06 or 1.28 percent from the previous close. The quote was 47.03 percent below its 52-week high of USD 8.74, keeping the development-stage biotechnology company firmly in a high-volatility setup.

Quarterly loss beats estimates

Unicycive's latest reported period was Q2 2026, ended June 30, 2026, according to its Investor Relations page. The company reported quarterly EPS of USD -0.06, compared with a USD -0.47 consensus estimate, a USD 0.41 improvement versus expectations, as MarketBeat reported on September 7, 2026.

The comparison matters because Unicycive is still building a commercial pipeline rather than reporting product revenue. Its lead candidate, oxylanthanum carbonate, is being developed as a phosphate binder for hyperphosphatemia in patients with chronic kidney disease who receive dialysis, while UNI-494 targets acute kidney injury, according to the company's September 1, 2026 release.

Analyst target remains distant

MarketBeat reported a Moderate Buy consensus from seven research firms on September 7, 2026, with five buy ratings, one hold and one sell. The average 12-month price target was USD 18.75, which stands USD 14.12 above the September 28, 2026 quote and highlights the gap between development-stage expectations and the current market value.

The same overview said H.C. Wainwright cut its target from USD 22.00 to USD 15.00 on June 30, 2026, while B. Riley reduced its target from USD 22.00 to USD 20.00 on August 12, 2026. Those revisions provide a counterweight to the positive consensus and keep regulatory execution central to the valuation discussion.

UNCY trades near its lower range

Unicycive shares traded between USD 4.53 and USD 4.67 on September 28, 2026, with volume of 354,198 shares. The market capitalization was USD 123.8 million, while the 52-week range extended from USD 3.93 to USD 8.74.